ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1867

Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics

Laura Much1, Elena Pachera2, Havard Fretheim3, Knut EA Lundin4, Lumeng Li5, Astrid Hofman6, Pietro Bearzi5, Philip Stauffer1, Michael Scharl7, Oyvind Molberg8, Oliver Distler9 and Anna-Maria Hoffmann-Vold3, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2University Hospital Zurich, Zurich, Switzerland, 3Oslo University Hospital, Oslo, Norway, 4Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, 6Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, 7Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 8Oslo University Hospital, Oslo, Nepal, 9Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland

Meeting: ACR Convergence 2025

Keywords: Bioinformatics, Gene Expression, Inflammation, interferon, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1855–1876) Systemic Sclerosis & Related Disorders – Basic Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: SSc frequently results in serious gastrointestinal (GI) complications that contribute to increased morbidity and mortality. Understanding the molecular changes across different disease stages is crucial for elucidating the pathophysiology. Our study employs high-definition spatial transcriptomics to decipher the molecular and cellular landscape of the GI, assessing distinct alterations in the lamina propria associated with early and late disease stages.

Methods: We studied gastroduodenal biopsies from SSc patients enrolled in the ReSScue trial (n=10, 2013 ACR/EULAR classification criteria). Patients presented moderate to severe lower GI symptoms assessed by the UCLA GIT score. Formalin-fixed paraffin-embedded (FFPE) samples were processed for spatial transcriptomics using the Visium HD Spatial Gene Expression Reagent kit v1. Libraries were sequenced on the Illumina NovaSeq X platform and alignment was performed with Space Ranger 3.1.3. The data was analyzed using the packages Seurat v5 and Banksy for cell typing. Speckle was used for compositional analysis between SSc patients with early (symptom onset < 3.5 years) and late stage disease (symptom onset > 13.5 years). Differentially expressed genes (DEG) were identified between early and late patients using MAST (adjusted p-value < 0.05, |log2 FC| ≥ 0.2) and the clusterProfiler package was used for pathway over-representation analysis (ORA) and gene set enrichment analysis (GSEA) with the Gene Ontology (GO) database.

Results: We included 5 SSc patients with early and 5 with late stage, with mean disease durations of 1.9 years and 18.6 years, respectively. The two groups did not differ in other clinical parameters (Fig. 1). Six tissue domains were annotated: Epithelium (villi), crypts, lamina propria, Brunner’s glands, muscularis mucosae and isolated lymphoid follicles (ILF; Fig. 2A-B). Compositional analysis between early and late disease showed no significant differences in the tissue regions (Fig. 2C). DEG of the lamina propria revealed 61 significantly upregulated genes and 2,355 significantly downregulated genes in early compared to late disease (Fig. 3A). ORA showed upregulated pathways related to pathogen defense (GBP3, GBP5, LYZ, CHGA) in early compared to late disease (Fig. 3B). In contrast, several pathways associated with extracellular matrix (ECM) organization, including ADAM19 and various collagen types, were significantly downregulated in early compared to late disease (Fig. 3C). Also, both ORA and GSEA showed downregulation in early SSc of immune response pathways, including JAK-STAT signaling and interferon responses (e.g., JAK1, STAT2, IRF8, IRF4), and pathways related to actin cytoskeleton organization and angiogenesis (e.g. CAPZA2, GSN, VEGFA, VEGFB; Fig. 3C).

Conclusion: This is a first report investigating the molecular landscape in GI tissue of SSc patients using high-definition spatial transcriptomics across different disease stages. Our findings could allude to the importance of exogenous agents in early disease stages, with an upregulation of pathogen defense pathways in early SSc. In addition, our results show an upregulation of fibrosis pathways and ongoing inflammatory processes in late SSc.

Supporting image 1Fig. 1: Characteristics and clinical data for SSc patients with early and late disease.

mRSS = modified Rodnan skin score, ILD = Interstitial lung disease. * symptoms assessed by the UCLA GIT score.

Supporting image 2Fig. 2: Spatial transcriptomic analysis reveals 6 distinct tissue regions in the duodenum of SSc patients. A) UMAP of all 10 samples (908,423 8×8µm bins) and representative spatial plots of 1 sample show 6 distinct tissue regions. B) A dotplot of the 6 identified tissue regions shows the top 5 expressed marker genes in each cluster, which were used for manual annotation. C) Compositional analysis shows no significant differences in the proportions of the tissue regions between early and late SSc patients.

Supporting image 3Fig. 3: DEG of the lamina propria show downregulated genes and pathways related to immune response and ECM in early compared to late patients. A) Volcano plot of 61 significantly upregulated and 2,355 significantly downregulated genes in early compared to late SSc, highlighting genes related to the pathways identified by GO. Upregulated genes are marked in yellow. B) ORA with the GO database shows upregulated pathways related to pathogen defense in early SSc (red boxes). C) ORA with the GO database shows downregulated pathways related to immune response (red boxes), ECM organization (green boxes) and actin cytoskeleton organization (blue boxes) in early compared to late SSc.


Disclosures: L. Much: None; E. Pachera: None; H. Fretheim: Boehringer-Ingelheim, 6; K. Lundin: None; L. Li: None; A. Hofman: None; P. Bearzi: None; P. Stauffer: None; M. Scharl: None; O. Molberg: None; O. Distler: 4P-Pharma, 2, 6, AbbVie/Abbott, 2, 6, Acceleron, 2, 6, Acepodia Biotech, 2, 6, Aera, 2, 6, AnaMar, 2, 6, Anaveon AG, 2, 6, Argenx, 2, 6, AstraZeneca, 2, 6, BMS, 2, 5, 6, Calluna (Arxx), 2, 6, Cantargia AB, 2, 6, CITUS AG, 8, CSL Behring, 2, 6, EMD Serono, 2, 6, Galapagos, 2, 6, Galderma, 2, 6, Gossamer, 2, 6, Hemetron, 2, 5, 6, Innovaderm, 2, 5, 6, Janssen, 2, 6, Mediar, 2, 5, 6, mir-29 for the treatment of systemic sclerosis, 10, Mitsubishi Tanabe, 2, 5, 6, MSD Merck, 2, 6, Nkarta Inc., 2, 6, Novartis, 2, 6, Orion, 2, 6, Pilan, 2, 6, Prometheus, 2, 6, Quell, 2, 6, Sumitomo, 2, 5, 6, Topadur, 2, 5, 6, UCB, 2, 5, 6; A. Hoffmann-Vold: AbbVie, 2, Avalyn, 2, Boehringer Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard., Bristol-Myers Squibb, 2, Calluna Pharma, 2, Genentech, 2, Janssen, 2, 5, 6, Medscape, 2, 6, Merck Sharp & Dohme, 2, 6, Novartis, 6, Pliant Therapeutics, 2, Roche, 2, 6, Werfen, 2.

To cite this abstract in AMA style:

Much L, Pachera E, Fretheim H, Lundin K, Li L, Hofman A, Bearzi P, Stauffer P, Scharl M, Molberg O, Distler O, Hoffmann-Vold A. Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/deciphering-the-molecular-landscape-of-the-small-intestine-in-early-and-late-ssc-using-high-definition-spatial-transcriptomics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deciphering-the-molecular-landscape-of-the-small-intestine-in-early-and-late-ssc-using-high-definition-spatial-transcriptomics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology